You are here: Industry Insights > Novartis

News List

Novartis Drug Zykadia Receives FDA Priority Review for First-Line Use in Patients with ALK+ Metastat americanpharmaceuticalreview
February 24, 2017
Novartis announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients w
Novartis, NHS joint working pact delivers new eye service pharmatimes
February 21, 2017
People living in Ayrshire and Arran who have some of the most common forms of avoidable sight loss will now be able to benefit from a new facility designed specifically for the eye service through a partnership between Novartis Pharmaceuticals UK and the
Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland pharmaceutical-technology
February 21, 2017
Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss.
Ionis and Akcea to Collaborate with Novartis to Develop and AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx americanpharmaceuticalreview
February 20, 2017
Ionis Pharmaceuticals and Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., have closed on their exclusive, worldwide option and collaboration agreement with Novartis to develop and commercialize AKCEA-APO(a)-LRx and AKCEA-APOC
Novartis Says Court Battle Will Delay Its Enbrel Copy Until 2018 at Least firstwordpharma
January 26, 2017
Novartis said that a legal battle will delay the launch of Erelzi, a biosimilar of Amgen's Enbrel, until at least next year, as reported The New York Times Wednesday.
Novartis delivered solid 2016 performance worldpharmanews
January 26, 2017
Novartis announced today that the net sales were USD 48.5 billion (-2%, 0% cc) in the full year, as volume growth of 6 percentage points was offset by the negative impact of generic competition (-4 percentage points) and pricing (-2 percentage points).
Novartis invests in Ionis’ therapies to reduce cardiovascular risk europeanpharmaceuticalreview
January 11, 2017
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels o
Novartis Invests in Next Generation Therapies to Reduce Cardiovascular Risk in Patients with Underly americanpharmaceuticalreview
January 09, 2017
Novartis has announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering f

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page